Intended Use:
Zepbound® (tirzepatide) is a once-weekly injectable prescription medication approved for chronic weight management in adults with:

• A body mass index (BMI) ≥30 kg/m² (obesity), or
• A BMI ≥27 kg/m² (overweight) with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, obstructive sleep apnea, or dyslipidemia).
  It is to be used in combination with a reduced-calorie diet and increased physical activity.
  
  

Contraindications:
Do not use Zepbound® if:

• You or a family member has ever had medullary thyroid carcinoma (MTC)
• You have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• You are allergic to tirzepatide or any of its ingredients
  
  

Warnings & Serious Risks:

• Thyroid tumors, including cancer: In animal studies, tirzepatide caused thyroid C-cell tumors. Human relevance is uncertain.
• Pancreatitis: Discontinue use and contact your healthcare provider if you experience persistent, severe abdominal pain, especially if radiating to the back or accompanied by vomiting.
• Gallbladder disease: Watch for symptoms like upper abdominal pain, jaundice, or pale stools.
• Kidney impairment: GI side effects can cause dehydration, which may worsen kidney function.
• Hypoglycemia: Especially when used with insulin or insulin secretagogues.
• Diabetic retinopathy: Monitor for any changes in vision.
• Suicidal ideation or mood changes: Report behavioral or emotional changes promptly.
• Severe gastrointestinal disease: Use is not recommended in patients with a history of severe GI disorders.
  
  

Common Side Effects:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Indigestion
• Abdominal discomfort
• Injection site reactions
• Decreased appetite
• Fatigue
• Headache
• Flatulence
• Belching

Most side effects are transient and may lessen over time.

Drug Interactions:

• May delay gastric emptying, impacting the absorption of oral medications.
• Use caution when combining with:
  • Insulin or sulfonylureas
  • Oral contraceptives (alternative methods may be necessary temporarily)
  • Medications with narrow therapeutic indexes (e.g., warfarin)
    
    

Pregnancy & Breastfeeding:

• Not recommended during pregnancy. Discontinue at least 2 months prior to planned conception.
• Unknown if tirzepatide is excreted in breast milk. Avoid use while breastfeeding unless specifically advised by your provider.
  
  

Administration:
Inject subcutaneously once weekly in the abdomen, thigh, or upper arm. Administer on the same day each week, with or without food. Rotate injection sites with each dose.

Storage:
Refrigerate at 36°F to 46°F (2°C to 8°C). Do not freeze. If needed, Zepbound® pens can be stored at room temperature (up to 86°F / 30°C) for up to 21 days.

Emergency Situations:
Contact your healthcare provider or call 911 immediately if you experience signs of a serious allergic reaction, pancreatitis, low blood sugar, or persistent vomiting.

Disclaimer:
This information is for educational purposes only and does not replace medical advice. Always consult your healthcare provider before starting, stopping, or modifying any medication. Adverse events may be reported to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.